Similar articles

• A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

  Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team. Ledgerwood JE, et al. Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27. Vaccine. 2010. PMID: 21034824 Clinical Trial.
• Early trials of Ebola vaccine show immune response.

  Mayor S. Mayor S. BMJ. 2015 Apr 8;350:h1844. doi: 10.1136/bmj.h1844. BMJ. 2015. PMID: 25855620 No abstract available.
• Approaches to demonstration of Ebola virus vaccine efficacy.

  Krause PR, Cavaleri M, Coleman G, Gruber MF. Krause PR, et al. Lancet Infect Dis. 2015 Jun;15(6):627-9. doi: 10.1016/S1473-3099(15)00027-4. Epub 2015 May 17. Lancet Infect Dis. 2015. PMID: 26008825 No abstract available.
• Adenovirus-vectored Ebola vaccines.

  Gilbert SC. Gilbert SC. Expert Rev Vaccines. 2015;14(10):1347-57. doi: 10.1586/14760584.2015.1077122. Epub 2015 Aug 11. Expert Rev Vaccines. 2015. PMID: 26289977 Review.
• Immunology of protection from Ebola virus infection.

  Krause PR, Bryant PR, Clark T, Dempsey W, Henchal E, Michael NL, Regules JA, Gruber MF. Krause PR, et al. Sci Transl Med. 2015 May 6;7(286):286ps11. doi: 10.1126/scitranslmed.aaa8202. Sci Transl Med. 2015. PMID: 25947159 Review.